Paige, a medical technology company transforming the work of pathologists using robust AI applications and AI-powered platforms, has launched the second generation of Virchow— a multimodal AI system for cancer diagnostics.
Virchow2 is the largest and the world’s most advanced AI model in clinical pathology, adding to the company’s suite of foundational AI models.
Unlike the previous versions, Paige’s Virchow2G and Virchow2 provide a deeper analysis of cells and tissues, extending their capabilities in pathology and cancer diagnosis beyond the existing models.
Dr. Thomas Fuchs, founder and Chief Scientist of Paige, said the new model was developed in collaboration with Microsoft. Dr. Fuchs added that the new models will expand the understanding of cancer cells through computational pathology.
This could unlock critical information vital in developing future ground-breaking innovations, which could result in precise diagnosis and the development of more targeted cancer therapies for personalized care.
Revolutionizing Cancer Diagnostics
Paige has used the foundational AI model to develop applications that help pathologists identify and diagnose cancer in more than 40 tissue types.
Unlike traditional diagnosis methods, which are time-consuming and still prone to error, the new AI models can help pathologists quickly identify rare types of cancer with impressive accuracy.
The model highlights areas of concern, helping pathologists further assess and diagnose accurately, enabling novel biomarker identification, therapeutic targeting, and optimization of clinical trial design.
In addition to cancer detection models that help understand the associated genetic biomarkers, Paige has also developed advanced pre-built AI models for research entities, pharmaceuticals, and life sciences.
Due to its advanced capabilities surpassing the performance of the previous models, Virchow has earned recognition in Nature Medicine.